Signifor: new treatment for Cushing's disease

Signifor is the first targeted treatment for Cushing's disease, an endocrine disorder caused by excessive cortisol production resulting from an underlying pituitary tumour.

The recommended starting dose of Signifor is 600 microgram by subcutaneous injection twice daily.
The recommended starting dose of Signifor is 600 microgram by subcutaneous injection twice daily.


Pasireotide is a novel cyclohexapeptide somatostatin analogue. It binds with high affinity to four of the five somatostatin receptor subtypes.1 Activation of these receptors on ACTH-secreting pituitary tumours inhibits the excessive production of ACTH that leads to the symptoms of Cushing’s disease.


The efficacy and safety of pasireotide in the treatment of Cushing’s disease were assessed in a randomised, double-blind phase III trial (n=162), involving adult patients with urinary-free cortisol (UFC) levels at least 1.5 times the upper limit of normal.2 Pasireotide was administered by subcutaneous injection twice daily. The primary endpoint was normalisation of UFC at six months, defined as a level at or below the upper limit of normal, with no prior dose increase.

After six months, mean UFC levels had normalised in 14.6% (95% CI 7.0–22.3) of patients receiving pasireotide 600 microgram twice daily and in 26.3% (95% CI 16.6–35.9) of those receiving 900 microgram twice daily. The primary endpoint was therefore determined to have been met in the 900 microgram group.1,2

Decreases in blood pressure, BMI and total cholesterol were observed at six months in patients with both full and partial mean UFC control.1

Pasireotide was associated with hyperglycaemia-related adverse events in 73% of patients; other adverse effects were similar to those observed with other somatostatin analogues.2

Novartis is currently undertaking a phase III trial to evaluate a longer-acting form of pasireotide that only requires injection once a month.


1.    Signifor Summary of Product Characteristics, April 2012.
2.    Colao A et al. N Engl J Med 2012; 366: 914-24.

View Signifor drug record

Further information: Novartis

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases